Home » Stocks » ORGO

Organogenesis Holdings, Inc. (ORGO)

Stock Price: $10.03 USD -0.83 (-7.64%)
Updated Jan 21, 2021 1:37 PM EST - Market open
Market Cap 1.39B
Revenue (ttm) 306.14M
Net Income (ttm) -4.94M
Shares Out 105.04M
EPS (ttm) -0.06
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 21
Last Price $10.03
Previous Close $10.86
Change ($) -0.83
Change (%) -7.64%
Day's Open 11.01
Day's Range 9.86 - 11.05
Day's Volume 2,232,112
52-Week Range 2.86 - 11.05

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Zacks Investment Research - 1 day ago

ORGANOGENESIS (ORGO) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

24/7 Wall Street - 5 days ago

While most of Wall Street focuses on large- and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.

Other stocks mentioned: MRO, WPRT, BIOL, KERN
The Motley Fool - 1 week ago

The company announced its preliminary fourth-quarter financial results.

GlobeNewsWire - 1 week ago

CANTON, Mass., Jan. 14, 2021 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture and commercializati...

CNBC - 1 week ago

These are the stocks posting the largest moves after the bell on Wednesday.

Other stocks mentioned: ETH, JWN
GlobeNewsWire - 1 week ago

CANTON, Mass., Jan. 13, 2021 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercializat...

GlobeNewsWire - 1 week ago

FDA Determines ReNu Preliminary Clinical Evidence Indicates Potential to Address Unmet Medical Needs for the Management of Symptoms Associated with Knee Osteoarthritis

Zacks Investment Research - 2 weeks ago

New strain of coronavirus, growing demand for digitization and past record indicate that the Nasdaq can win in 2021 too after its best year since 2009.

Other stocks mentioned: AEIS, AOSL, COHU, UCTT
GlobeNewsWire - 2 weeks ago

CANTON, Mass., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercializat...

Zacks Investment Research - 1 month ago

Organogenesis (ORGO) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Benzinga - 2 months ago

Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason -- they believe the stock price will rise and they want to profit from it. So insider b...

Other stocks mentioned: CAR, BH, GSKY, GTHX, KROS, REYN, WTRH
Seeking Alpha - 2 months ago

Organogenesis is a revenue-generating regenerative medicines company with a long pipeline. The company has decades of operating history behind it.

GlobeNewsWire - 2 months ago

CANTON, Mass., Nov. 13, 2020 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercializat...

GlobeNewsWire - 2 months ago

CANTON, Mass., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercializat...

Seeking Alpha - 2 months ago

Organogenesis Holdings Inc. (ORGO) CEO Gary Gillheeney on Q3 2020 Results - Earnings Call Transcript

GlobeNewsWire - 2 months ago

CANTON, Mass., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercializat...

GlobeNewsWire - 2 months ago

CANTON, Mass., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture and commercializati...

The Motley Fool - 3 months ago

The company released preliminary third-quarter results.

GlobeNewsWire - 3 months ago

CANTON, Mass., Oct. 14, 2020 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercializat...

GlobeNewsWire - 4 months ago

CANTON, Mass., Sept. 17, 2020 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commerciali...

GlobeNewsWire - 4 months ago

CANTON, Mass., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commerciali...

GlobeNewsWire - 4 months ago

CANTON, Mass., Aug. 24, 2020 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercializ...

Seeking Alpha - 5 months ago

Organogenesis Holdings, Inc. (ORGO) CEO Gary Gillheeney on Q2 2020 Results - Earnings Call Transcript

Zacks Investment Research - 5 months ago

Organogenesis (ORGO) delivered earnings and revenue surprises of 58.33% and 0.97%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

GlobeNewsWire - 5 months ago

CANTON, Mass., Aug. 10, 2020 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercializ...

Zacks Investment Research - 5 months ago

Organogenesis (ORGO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GlobeNewsWire - 5 months ago

CANTON, Mass., July 23, 2020 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture and commerciali...

GlobeNewsWire - 6 months ago

CANTON, Mass., July 15, 2020 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercializ...

Seeking Alpha - 8 months ago

Organogenesis Holdings, Inc. (ORGO) CEO Gary Gillheeney on Q1 2020 Results - Earnings Call Transcript

Zacks Investment Research - 8 months ago

Organogenesis (ORGO) delivered earnings and revenue surprises of -33.33% and 0.71%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

GlobeNewsWire - 9 months ago

CANTON, Mass., April 13, 2020 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture and commercial...

Zacks Investment Research - 9 months ago

Organogenesis Holdings has been struggling lately, but the selling pressure may be coming to an end soon.

Seeking Alpha - 10 months ago

Organogenesis Holdings Inc. (ORGO) CEO Gary S.

Seeking Alpha - 10 months ago

Organogenesis: Undervalued And Promising Investment Opportunity For 2020

The Motley Fool - 1 year ago

Find out what punished these unfortunate stocks.

Other stocks mentioned: PSTG, VHC
The Motley Fool - 1 year ago

The regenerative medicine company announced the pricing of a public stock offering.

About ORGO

Organogenesis Holdings, a regenerative medicine company, focuses on the development, manufacture, and commercialization of solutions for the advanced wound care, and surgical and sports medicine markets primarily in the United States. The company's advanced wound care products include Apligraf for the treatment of venous leg ulcers and diabetic foot ulcers (DFUs); Dermagraft for treating DFUs; PuraPly AM to address biofilm across a range of wound types; and Affinity and NuShield to address various wound sizes and types. Its surgical and sports ... [Read more...]

Industry
Drug Manufacturers-Specialty & Generic
Founded
1985
CEO
Gary S. Gillheeney Sr.
Employees
835
Stock Exchange
NASDAQ
Ticker Symbol
ORGO
Full Company Profile

Financial Performance

In 2019, ORGO's revenue was $260.98 million, an increase of 34.91% compared to the previous year's $193.45 million. Losses were -$40.45 million, -37.60% less than in 2018.

Financial Statements

Analyst Forecasts

According to 4 analysts, the average rating for ORGO stock is "Strong Buy." The 12-month stock price forecast is 11.50, which is an increase of 14.66% from the latest price.

Price Target
$11.50
(14.66% upside)
Analyst Consensus: Strong Buy